Diadema Partners’s Stoke Therapeutics STOK Stock Holding History

Diadema Partners’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-17,181	Closed	-$545K	–	202
2025 Q4	$545K	Buy	+17,181	New	+$516K	0.09%	112

Other funds holding STOK

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Diadema Partners's STOK Position: Q1 2026 in Review

Diadema Partners sold out of Stoke Therapeutics (STOK) in Q1 2026, closing a stake of 17,181 shares — an estimated $545K sold.

Diadema Partners first reported a position in STOK in Q4 2025 and held it in 1 quarter. The position peaked at $545K in Q4 2025. 198 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

Diadema Partners reported no remaining Stoke Therapeutics position as of Q1 2026 after selling out during the quarter.
Diadema Partners sold 17,181 Stoke Therapeutics shares in Q1 2026, an estimated $545K.
Diadema Partners first reported a position in Stoke Therapeutics in Q4 2025 and held it in 1 quarter.
Diadema Partners's Stoke Therapeutics position peaked at $545K in Q4 2025.
198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on Diadema Partners's 13F filing for Q1 2026, filed 15 May 2026.